In a nutshell This study aimed to investigate the occurrence of hematological (blood-related) side effects in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. This study concluded that bone marrow fibrosis at diagnosis was a predictor of hematological side effects from tyrosine...
Read MoreLeukemia Posts on Medivizor
Evaluating ponatinib in recurrent Philadelphia chromosome positive central nervous system leukemia
In a nutshell This study aimed to investigate ponatinib combined with conventional therapy in recurrent Philadelphia chromosome-positive central nervous system leukemia with a BCR-ABL T315I mutation after allogeneic hematopoietic stem cell transplant. This study concluded that ponatinib may be effective for these...
Read MoreOfatumumab maintenance in patients with relapsed chronic lymphocytic leukemia
In a nutshell This study aimed to investigate the use of ofatumumab maintenance treatment in patients with relapsed chronic lymphocytic leukemia. This study concluded that this treatment significantly prolonged progression-free survival in these patients and was well tolerated. Some background Ofatumumab (Arzerra) is a...
Read MoreMinimal residual disease status after inotuzumab ozogamicin in patients with relapsed/refractory acute lymphoblastic leukemia
In a nutshell This study aimed to investigate if minimal residual disease negativity is useful as a prognostic factor after inotuzumab ozogamicin treatment in patients with relapsed/refractory acute lymphoblastic leukemia. This study concluded minimal residual negativity with complete remission is associated with a better...
Read MoreWhich factors affect the safety and effectiveness of imatinib treatment for newly diagnosed chronic myeloid leukemia?
In a nutshell This study aimed to investigate the safety and effectiveness of imatinib treatment in patients with newly diagnosed chronic myeloid leukemia. This study concluded that patients of lower weight and older age are more vulnerable to side effects. Some background Imatinib (Gleevec) is a targeted therapy...
Read MoreThe treatment of standard-risk B-cell acute lymphoblastic leukemia with intensified postinduction therapy
In a nutshell This study evaluated if the intensified postinduction therapy is safe and effective to treat children with standard-risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study concluded that the treatment excellently impacted survival among patients, but further intensifying the therapy might be unnecessary. Some background B-ALL is...
Read MoreValproate and retinoic acid with decitabine in elderly patients with acute myeloid leukemia
In a nutshell This study aimed to investigate the effects of valproate (Depakene) and all-trans retinoic acid (ATRA) in treatment-naive elderly patients with acute myeloid leukemia. This study concluded that the addition of ATRA to decitabine (Dacogen) chemotherapy led to a higher remission rate and survival...
Read MoreLooking for patients with AML to try a combination treatment
In a nutshell This trial is evaluating the effectiveness of KRT-232 for the treatment of acute myeloid leukemia (AML). The main outcomes are the number of patients who achieve complete remission, and how many patients stop treatment due to side effects. This study is being conducted in Columbus, Ohio, United States. The details AML is a...
Read MoreManaging advanced phase chronic myeloid leukemia
In a nutshell This study reviewed treatment options for advanced phase chronic myeloid leukemia. This study concluded that managing advanced phase chronic myeloid leukemia remains challenging and treatment options include tyrosine kinase inhibitors, chemotherapy, and transplant. Some background Chronic myeloid leukemia (CML) can be...
Read MoreComparing new-generation tyrosine kinase inhibitors and imatinib in patients with newly diagnosed chronic myeloid leukemia
In a nutshell This study aimed to compare the effectiveness of new-generation tyrosine kinase inhibitors and imatinib in patients with newly diagnosed chronic myeloid leukemia. This study concluded that for first-line treatment, new-generation tyrosine kinase inhibitors are better than imatinib. Some background Tyrosine...
Read MoreSearching for patients with relapsed or unresponsive chronic lymphocytic leukemia to test an immune cell-stimulating treatment
In a nutshell This study is looking for patients with relapsed or unresponsive chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) to test IOV-2001, a treatment that boosts cancer-killing immune cells. The main outcome that will be measured is how well patients respond to treatment. This study is recruiting in Columbus, OH,...
Read MoreAre the currently prescribed doses of tyrosine kinase inhibitors too high for elderly patients with chronic myeloid leukemia?
In a nutshell This study investigated the prescribed doses of tyrosine kinase inhibitors (TKIs) and the outcomes of elderly patients with chronic myeloid leukemia (CML). The study concluded that the currently prescribed TKI dose might be higher than necessary in elderly patients. Some background TKIs such as imatinib (Glivec), dasatinib...
Read More
